OncoGenex Pharmaceuticals, Inc.
) recently announced that it is looking to move its oncology
candidate, OGX-427, into a phase II study, Spruce, for the
potential treatment of previously untreated advanced non-squamous
non-small cell lung cancer (NSCLC).
The investigator-sponsored, randomized, double-blind,
placebo-controlled phase II study will evaluate whether
progression-free survival (PFS) outcomes can be improved by
adding OGX-427 to carboplatin and pemetrexed therapy.
In the Spruce study, patients with non-squamous NSCLC will be
randomized to receive carboplatin and pemetrexed therapy plus
either OGX-427 or placebo.
Spruce is the fifth phase II study being conducted with
OGX-427 after Borealis-1, Borealis-2, Pacific and OGX-427-PR01.
The Borealis-1 study is designed to evaluate the survival
benefit, safety and tolerability of combining OGX-427 with
gemcitabine and cisplatin in the first-line treatment of patients
with advanced bladder cancer. The Borealis-2 study is being
conducted in patients suffering from advanced or metastatic
bladder cancer whose disease has progressed following initial
platinum-based chemotherapy treatment.
The Pacific study is evaluating the benefit of OGX-427 plus
Johnson & Johnson's (
Zytiga in men with castration-resistant prostate cancer
(CRPC) while OGX-427-PR01 is evaluating the benefit of OGX-427
plus prednisone in CRPC patients.
The most advanced candidate in OncoGenex' pipeline is
custirsen, which is being studied for three indications under
phase III trials, namely, Affinity (second-line CRPC), Enspirit
(advanced NSCLC) and Synergy (chemotherapy - naive CRPC)
OncoGenex has a global collaboration and license agreement
Teva Pharmaceutical Industries Ltd.
) for custirsen.
OncoGenex and Teva currently carry a Zacks Rank #3 (Hold).
Currently, companies like
) look more attractive with a Zacks Rank #1 (Strong Buy).
JOHNSON & JOHNS (JNJ): Free Stock Analysis
ONCOGENEX PHARM (OGXI): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.